NCT03193645已完成不适用
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Occurrence of cardiovascular comorbidity
研究概览
简要总结
The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced.
This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male aged 18 years or older
- •Diagnosed with prostate cancer
- •Patient having received an antagonist of GnRH Degarelix prescription.
- •Agreeing to and capable of completing in French during the visits all questionnaires on the impact of their illness and treatment.
- •Patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written Informed Consent Form.
排除标准
- •Patient included in an interventional study assessing treatment for prostate cancer.
- •Patient presenting hypersensitivity to Degarelix or one of its excipients.
- •Patient treated by other hormonotherapy.
研究组 & 干预措施
Degarelix
干预措施: Degarelix (Drug)
结局指标
主要结局
Occurrence of cardiovascular comorbidity
时间窗: At inclusion
Measured by a history of at least one cardiovascular illness (according to ICD-10) and/or at least three cardiovascular risk factors (as defined by Cancer Committee of the French Urology Association)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Diagnostics of Coronavirus Disease 2019 Cardiovascular ComplicationsCOVID-19Endothelial FunctionDiastolic DysfunctionOxygen ConsumptionQuality of LifeExercise ToleranceNCT05608603I.M. Sechenov First Moscow State Medical University100
Unknown
不适用
Cardiovascular Risk in Toledo PopulationCardiovascular Risk FactorCardiovascular DiseasesNCT03294369Castilla-La Mancha Health Service3,125
撤回
不适用
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)Metabolic SyndromeNCT02069717Daewoong Pharmaceutical Co. LTD.
已完成
不适用
AN OBSERVATIONAL STUDY ON CARDIOVASCULAR INVOLVEMENT IN COVID RECOVERED PATIENTSGender DiscriminationCardiac EventComplicationNCT05710796Kakatiya University500
已完成
不适用
Observational Prospective Study OPTIMA II - Follow-upMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)NCT02099565AstraZeneca572